Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: The impact of the waiting time

Haematologica

Volumn 93, Issue 6, 2008, Pages 925-929

  Balduzzi, Adriana ^a,i   De Lorenzo, Paola ^a   Schrauder, André ^b   Conter, Valentino ^a   Uderzo, Cornelio ^a   Peters, Christina ^c   Klingebiel, Thomas ^d   Stary, Jan ^e   Felice, Maria S ^f   Magyarosy, Edina ^g   Schrappe, Martin ^b   Dini, Giorgio ^h   Gadner, Helmut ^c   Valsecchi, Maria Grazia ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^g SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^h G GASLINI INSTITUTE   (Italy)

ⁱ SAN GERARDO HOSPITAL   (Italy)

Author keywords

Acute lymphoblastic leukemia; Allogeneic transplantation; Childhood; Very high risk; Waiting time to transplant

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHILD; CHILDHOOD CANCER; DISEASE FREE SURVIVAL; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; ORGAN DONOR; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOPHENOTYPING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK; TIME FACTORS; TRANSLOCATION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 44949166375     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12291     Document Type: Article

References (10)

1. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, et al. Chemotherapy versus allogeneic transplantation in childhood very high risk acute lymphoblastic leukaemia in first complete remission: a comparison by genetic randomization in an international prospective study. Lancet 2005;366:635-42.
2. Saarinen-Pihkala UM, Gustafsson G, Ringden O, Heilmann C, Glomstein A, Lonnerholm G, et al. No disadvantages in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukaemia in second remission. J Clin Oncol 2001;19:3406-14.
3. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Uderzo C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002;16:2228-37.
4. Woolfrey AE, Anasetti C, Storer B, Doney K, Milner LA, Sievers EL, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002;99:2002-8.
5. Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH, et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukemia in childhood: similar survival after matched-related and matched-unrelated donor transplant. Br J Haematol 2002;116:483-90.
6. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002;16:2228-37.
7. Dini G, Valsecchi MG, Micalizzi C, Busca A, Balduzzi A, Arcese W, et al. Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission. Bone Marrow Transplant 2003;32:325-31.
8. Satwani P, Sather H, Ozkaynak F, Heerema NA, Schultz KR, Sanders J, et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukaemia: a Children's Oncology Group Study Report. Biol Blood Marrow Transplant 2007;13:218-27.
9. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and Tcell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;31[Epub ahead of print].
10. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL_BFM 90 and 95. J Clin Oncol 2006;24:5742-9.